|1.||Furuya, Ryoji: 4 articles (01/2013 - 03/2005)|
|2.||Hirao, Yoshihiko: 4 articles (01/2013 - 05/2004)|
|3.||Siddique, Yasir Hasan: 4 articles (11/2008 - 11/2004)|
|4.||Afzal, Mohammad: 4 articles (11/2008 - 11/2004)|
|5.||Murakoshi, M: 4 articles (08/2001 - 04/2000)|
|6.||Ohashi, Yasuo: 3 articles (01/2013 - 05/2004)|
|7.||Miyazawa, Katsuhito: 3 articles (01/2013 - 05/2006)|
|8.||Shibata, Yasuhiro: 3 articles (01/2013 - 04/2011)|
|9.||Fujimoto, Kiyohide: 3 articles (01/2013 - 05/2006)|
|10.||Arowojolu, Ayodele O: 3 articles (01/2012 - 01/2009)|
01/01/2008 - "Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study."
01/01/1970 - "An antiandrogen delta 1 chlormadinone acetate in acne: lack of effect topically."
01/01/2008 - "The highly statistically significant improvements in clinical findings and various biophysical skin parameters observed in this study suggest that the antiandrogenic oral contraceptive chlormadinone/ethinylestradiol may be a major therapy option in women with acne-prone skin who request hormonal contraception."
06/01/2004 - "cyproterone acetate, chlormadinone acetate) have demonstrated efficacy in the treatment of women with acne, although comparisons between trials are difficult because of differing endpoints. "
01/01/2008 - "The aim of this open-label, prospective, single-centre, phase IV study was to investigate the effects of an oral contraceptive containing chlormadinone 2 mg and ethinylestradiol 0.03 mg (Belara) on the physiology of acne-prone facial skin in healthy women aged 18-37 years. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/01/2013 - "The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study."
08/01/2001 - "The effect of chlormadinone acetate (CMA), a synthetic steroidal antiandrogen, on spontaneous benign prostatic hyperplasia (BPH) in dogs was investigated. "
08/01/2001 - "The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia."
07/01/2001 - "The effect of a synthetic steroidal antiandrogen, chlormadinone acetate (CMA), on spontaneous benign prostatic hyperplasia (BPH) in dogs was investigated. "
08/01/2000 - "The atrophic effect of a synthetic steroidal antiandrogen, chlormadinone acetate (CMA), on spontaneous benign prostatic hyperplasia (BPH) in dogs was investigated. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2013 - "To investigate the clinical efficacy of low-dose chlormadinone acetate (CMA) in prostate cancer patients who suffer from hot flushes that is a major side effect of androgen deprivation therapy. "
01/01/1999 - "To determine the efficacy of the antiandrogen chlormadinone acetate as a treatment option for stage A prostate cancer, a retrospective analysis of 111 patients who received chlormadinone acetate was done. "
04/01/2009 - "We prospectively studied the usefulness of chlormadinone acetate (CMA) as an alternative therapy for prostate cancer relapse after combined androgen blockade (CAB) therapy. "
04/01/2009 - "[Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy]."
08/01/1995 - "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer."
10/01/1987 - "Chlormadinone acetate, a progestational agent, has proved more effective against early prostatic carcinoma than against late-stage disease. "
09/01/1980 - "[The clinical effect of chlormadinone acetate on carcinoma of the prostate (author's transl)]."
08/01/1989 - "Two patients with focal and moderately differentiated carcinoma (stage A2) and three patients with stage A1 cancer were treated by means of chlormadinone acetate. "
01/01/1981 - "Based on the results obtained from animal experiments and from a pilot clinical trial on prostatic cancer patients using various antiandrogenic compounds, chlormadinone acetate (CMA) was selected for a clinical trial in patients with carcinoma of the prostate. "
01/01/1995 - "We investigated the efficacy of 2-week and 4-week pretreatments with 100 mg/day chlormadinone acetate (CMA) to prevent the flare reaction induced by luteinizing-hormone-releasing hormone (LHRH) in patients with metastatic carcinoma of the prostate. "
|5.||Neoplasm Metastasis (Metastasis)
10/01/1994 - "By administering chlormadinone acetate for prostatic hypertrophy, the pulmonary metastases improved dramatically. "
10/01/1973 - " Of 22 nodules from the chlormadinone-treated dogs 12 were nodular hyperplasia, 4 benign mixed mammary tumors, 1 chondromucoid degeneration and 1 adenocarcinoma with widespread metastases. "
|2.||Levonorgestrel (Plan B)
|4.||Gonadotropin-Releasing Hormone (GnRH)
|7.||Adrenocorticotropic Hormone (ACTH)
|8.||Ethinyl Estradiol (Estinyl)
|2.||Intrauterine Devices (Intrauterine Device)
|4.||Contraception (Birth Control)
|5.||Prostatectomy (Retropubic Prostatectomy)